Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LMRI
SELLLumexa Imaging Holdings, Inc. · Healthcare · United States · $1.1B · Avg Vol: $7M/d
COMPANY DESCRIPTION
Information for the ticker LMRI and company name 'Lumexa Imaging Holdings, Inc.' as a publicly traded entity is not readily available on major exchanges or widely recognized financial data providers. It may refer to a private entity, a delisted stock, or a ticker associated with a different company or financial instrument not in public circulation.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 935.9M | 948.9M | 1.0B | 4.6% | 1.0B | 1.1B | 1.1B | 4.9% |
| EPS | -1.76 | -1.35 | -0.66 | — | -0.39 | — | — | — |
| Shares | 94.6M | 94.6M | 96.1M | +1.6% | 96.1M | — | — | — |
| Debt | 1.3B | 1.3B | 962.5M | -14.1% | 967.4M | — | — | — |
| Equity | 198.4M | 161.7M | 586.1M | 71.9% | — | — | — | — |
| Op CF | 37.5M | 40.7M | 17.1M | -32.5% | 34.0M | — | — | — |
| Inv CF | -29.7M | -22.3M | -21.0M | — | — | — | — | — |
| Fin CF | -8.8M | -12.5M | 36.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LMRI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LMRI | Lumexa Imaging Holdings, Inc.(you) | $1.1B | 26 | SELL |
| TNDM | Tandem Diabetes Care, Inc. | $1.2B | 25 | SELL |
| ATEC | Alphatec Holdings, Inc. | $1.3B | 27 | SELL |
| AORT | Artivion, Inc. | $1.2B | 22 | SELL |
| BBNX | Beta Bionics, Inc. | $706M | 21 | SELL |
| CBLL | CeriBell, Inc. | $642M | 22 | SELL |
| PRCT | PROCEPT BioRobotics Corporation | $950M | 13 | STRONG SELL |
| BFLY | Butterfly Network, Inc. | $1.7B | 34 | SELL |
| NPCE | NeuroPace, Inc. | $505M | 32 | SELL |
| QDEL | QuidelOrtho Corporation | $1.1B | 47 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%